Alnylam Interest Income from 2010 to 2026

ALNY Stock

USD 332.92 1.68 0.51%

Alnylam Pharmaceuticals Interest Income yearly trend continues to be fairly stable with very little volatility. Interest Income is likely to outpace its year average in 2026. Interest Income is income earned from the investment of cash or from lending money to others, including interest from bank accounts, bonds, or other interest-bearing investments. View All Fundamentals

Interest Income

First Reported

2019-03-31

Previous Quarter

28.7 M

Current Value

26.6 M

Quarterly Volatility

12.3 M

Covid

Interest Hikes

Check Alnylam Pharmaceuticals financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Alnylam Pharmaceuticals' main balance sheet or income statement drivers, such as Depreciation And Amortization of 58.4 M, Interest Expense of 265.3 M or Other Operating Expenses of 3.4 B, as well as many indicators such as Price To Sales Ratio of 13.33, Dividend Yield of 0.0 or PTB Ratio of 69.31. Alnylam financial statements analysis is a perfect complement when working with Alnylam Pharmaceuticals Valuation or Volatility modules.

Build AI portfolio with Alnylam Stock

Check out the analysis of Alnylam Pharmaceuticals Correlation against competitors.

For more information on how to buy Alnylam Stock please use our How to Invest in Alnylam Pharmaceuticals guide.

The evolution of Interest Income for Alnylam Pharmaceuticals provides essential context for understanding the company's financial health trajectory. By analyzing this metric's behavior over time, investors can assess whether recent trends align with long-term patterns, and how Alnylam Pharmaceuticals compares to historical norms and industry peers.

Latest Alnylam Pharmaceuticals' Interest Income Growth Pattern

Below is the plot of the Interest Income of Alnylam Pharmaceuticals over the last few years. It is income earned from the investment of cash or from lending money to others, including interest from bank accounts, bonds, or other interest-bearing investments. Alnylam Pharmaceuticals' Interest Income historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Alnylam Pharmaceuticals' overall financial position and show how it may be relating to other accounts over time.

Interest Income

10 Years Trend

Slightly volatile

Compare to Others All Fundamentals

Interest Income

Timeline

Alnylam Interest Income Regression Statistics

	Arithmetic Mean	35,451,206
	Geometric Mean	15,961,073
	Coefficient Of Variation	126.01
	Mean Deviation	35,795,491
	Median	11,809,000
	Standard Deviation	44,672,716
	Sample Variance	1995.7T
	Range	120.4M
	R-Value	0.79
	Mean Square Error	787.3T
	R-Squared	0.63
	Significance	0.0001
	Slope	7,022,625
	Total Sum of Squares	31930.4T

Alnylam Interest Income History

	2026	117 M
	2025	111.5 M
	2024	122 M
	2023	95.6 M
	2022	24.8 M
	2021	1.6 M
	2020	11.8 M

Other Fundumenentals of Alnylam Pharmaceuticals

Net Interest Income

Alnylam Pharmaceuticals Interest Income component correlations

	Total Assets	Total Stockholder Equity	Net Debt	Retained Earnings	Accounts Payable	Short Term Investments	Total Liab	Total Current Assets	Property Plant Equipment	Current Deferred Revenue	Long Term Debt	Short Term Debt	Intangible Assets	Net Receivables	Common Stock	Net Tangible Assets	Capital Surpluse	Deferred Long Term Liab	Long Term Investments	Long Term Debt Total	Short Long Term Debt	Net Invested Capital	Net Working Capital	Capital Stock
Total Assets		-0.05	0.34	-0.96	0.92	0.8	0.94	1.0	0.96	0.21	0.9	0.47	0.9	0.87	0.82	-0.35	0.98	-0.6	-0.6	0.86	-0.84	-0.7	0.67	0.95
Total Stockholder Equity	-0.05		-0.63	0.2	-0.05	0.06	-0.38	-0.03	-0.08	0.08	-0.43	-0.25	-0.24	-0.12	0.19	0.89	0.04	-0.5	0.09	-0.47	-0.16	0.35	-0.41	-0.32
Net Debt	0.34	-0.63		-0.52	0.33	0.41	0.54	0.32	0.43	0.31	0.54	0.74	0.43	0.23	0.31	-0.56	0.33	0.09	-0.41	0.47	-0.33	-0.56	0.34	0.5
Retained Earnings	-0.96	0.2	-0.52		-0.9	-0.85	-0.96	-0.95	-0.97	-0.26	-0.94	-0.58	-0.91	-0.77	-0.85	0.43	-0.96	0.55	0.66	-0.88	0.85	0.81	-0.64	-0.95
Accounts Payable	0.92	-0.05	0.33	-0.9		0.64	0.87	0.92	0.92	0.03	0.87	0.48	0.83	0.8	0.74	-0.37	0.92	-0.56	-0.52	0.84	-0.77	-0.64	0.59	0.88
Short Term Investments	0.8	0.06	0.41	-0.85	0.64		0.74	0.78	0.79	0.52	0.69	0.53	0.64	0.51	0.93	-0.05	0.83	-0.69	-0.52	0.59	-0.79	-0.68	0.49	0.72
Total Liab	0.94	-0.38	0.54	-0.96	0.87	0.74		0.93	0.92	0.18	0.97	0.53	0.91	0.84	0.71	-0.62	0.9	-0.4	-0.59	0.96	-0.73	-0.77	0.77	0.99
Total Current Assets	1.0	-0.03	0.32	-0.95	0.92	0.78	0.93		0.95	0.19	0.89	0.46	0.9	0.88	0.8	-0.34	0.97	-0.6	-0.6	0.86	-0.83	-0.67	0.68	0.94
Property Plant Equipment	0.96	-0.08	0.43	-0.97	0.92	0.79	0.92	0.95		0.26	0.87	0.51	0.9	0.8	0.82	-0.33	0.98	-0.54	-0.73	0.81	-0.91	-0.79	0.54	0.93
Current Deferred Revenue	0.21	0.08	0.31	-0.26	0.03	0.52	0.18	0.19	0.26		0.09	0.12	0.02	0.01	0.41	0.22	0.24	-0.32	-0.2	-0.03	-0.32	-0.31	0.07	0.14
Long Term Debt	0.9	-0.43	0.54	-0.94	0.87	0.69	0.97	0.89	0.87	0.09		0.52	0.89	0.75	0.67	-0.66	0.86	-0.38	-0.53	0.98	-0.67	-0.74	0.79	0.96
Short Term Debt	0.47	-0.25	0.74	-0.58	0.48	0.53	0.53	0.46	0.51	0.12	0.52		0.54	0.34	0.48	-0.34	0.46	-0.29	-0.46	0.46	-0.48	-0.49	0.29	0.52
Intangible Assets	0.9	-0.24	0.43	-0.91	0.83	0.64	0.91	0.9	0.9	0.02	0.89	0.54		0.84	0.66	-0.52	0.87	-0.39	-0.63	0.88	-0.74	-0.7	0.62	0.93
Net Receivables	0.87	-0.12	0.23	-0.77	0.8	0.51	0.84	0.88	0.8	0.01	0.75	0.34	0.84		0.53	-0.48	0.79	-0.35	-0.49	0.78	-0.62	-0.49	0.66	0.87
Common Stock	0.82	0.19	0.31	-0.85	0.74	0.93	0.71	0.8	0.82	0.41	0.67	0.48	0.66	0.53		0.01	0.87	-0.8	-0.5	0.57	-0.82	-0.62	0.42	0.7
Net Tangible Assets	-0.35	0.89	-0.56	0.43	-0.37	-0.05	-0.62	-0.34	-0.33	0.22	-0.66	-0.34	-0.52	-0.48	0.01		-0.23	-0.31	0.21	-0.74	0.03	0.36	-0.68	-0.6
Capital Surpluse	0.98	0.04	0.33	-0.96	0.92	0.83	0.9	0.97	0.98	0.24	0.86	0.46	0.87	0.79	0.87	-0.23		-0.65	-0.66	0.8	-0.91	-0.75	0.55	0.9
Deferred Long Term Liab	-0.6	-0.5	0.09	0.55	-0.56	-0.69	-0.4	-0.6	-0.54	-0.32	-0.38	-0.29	-0.39	-0.35	-0.8	-0.31	-0.65		0.14	-0.3	0.57	0.35	-0.19	-0.39
Long Term Investments	-0.6	0.09	-0.41	0.66	-0.52	-0.52	-0.59	-0.6	-0.73	-0.2	-0.53	-0.46	-0.63	-0.49	-0.5	0.21	-0.66	0.14		-0.48	0.85	0.61	-0.24	-0.61
Long Term Debt Total	0.86	-0.47	0.47	-0.88	0.84	0.59	0.96	0.86	0.81	-0.03	0.98	0.46	0.88	0.78	0.57	-0.74	0.8	-0.3	-0.48		-0.58	-0.66	0.83	0.95
Short Long Term Debt	-0.84	-0.16	-0.33	0.85	-0.77	-0.79	-0.73	-0.83	-0.91	-0.32	-0.67	-0.48	-0.74	-0.62	-0.82	0.03	-0.91	0.57	0.85	-0.58		0.72	-0.31	-0.74
Net Invested Capital	-0.7	0.35	-0.56	0.81	-0.64	-0.68	-0.77	-0.67	-0.79	-0.31	-0.74	-0.49	-0.7	-0.49	-0.62	0.36	-0.75	0.35	0.61	-0.66	0.72		-0.23	-0.72
Net Working Capital	0.67	-0.41	0.34	-0.64	0.59	0.49	0.77	0.68	0.54	0.07	0.79	0.29	0.62	0.66	0.42	-0.68	0.55	-0.19	-0.24	0.83	-0.31	-0.23		0.76
Capital Stock	0.95	-0.32	0.5	-0.95	0.88	0.72	0.99	0.94	0.93	0.14	0.96	0.52	0.93	0.87	0.7	-0.6	0.9	-0.39	-0.61	0.95	-0.74	-0.72	0.76

Click cells to compare fundamentals

About Alnylam Pharmaceuticals Financial Statements

Alnylam Pharmaceuticals investors use historical fundamental indicators, such as Alnylam Pharmaceuticals' Interest Income, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Alnylam Pharmaceuticals. Please read more on our technical analysis and fundamental analysis pages.

	Last Reported	Projected for Next Year
Interest Income	111.5 M	117 M
Net Interest Income	-141.2 M	-134.1 M

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

FSLY	Fastly Class A
MOB	Mobilicom Limited American
CMG	Chipotle Mexican Grill

Additional Tools for Alnylam Stock Analysis

When running Alnylam Pharmaceuticals' price analysis, check to measure Alnylam Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Alnylam Pharmaceuticals is operating at the current time. Most of Alnylam Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Alnylam Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Alnylam Pharmaceuticals' price. Additionally, you may evaluate how the addition of Alnylam Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2026 Macroaxis LLC

Alnylam Interest Income from 2010 to 2026

Latest Alnylam Pharmaceuticals' Interest Income Growth Pattern

Alnylam Interest Income Regression Statistics

Alnylam Interest Income History

Other Fundumenentals of Alnylam Pharmaceuticals

Alnylam Pharmaceuticals Interest Income component correlations

About Alnylam Pharmaceuticals Financial Statements

Also Currently Popular

Additional Tools for Alnylam Stock Analysis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY